Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Markers released top-line results today after previously reporting the trial succeeded.
We haven't written up this one. Ars Technica Health has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.